Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free TRML Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Tourmaline Bio (TRML) Competitors

Tourmaline Bio logo
Compare

TRML vs. CRSP, DNTH, LEGN, INDV, and CRNX

Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include CRISPR Therapeutics (CRSP), Dianthus Therapeutics (DNTH), Legend Biotech (LEGN), Indivior (INDV), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.

How does Tourmaline Bio compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Tourmaline Bio (NASDAQ:TRML) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Tourmaline Bio has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -16,569.77%. CRISPR Therapeutics' return on equity of -26.31% beat Tourmaline Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-16,569.77% -26.31% -22.30%
Tourmaline Bio N/A -30.50%-29.63%

In the previous week, CRISPR Therapeutics had 13 more articles in the media than Tourmaline Bio. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 0 mentions for Tourmaline Bio. CRISPR Therapeutics' average media sentiment score of 0.33 beat Tourmaline Bio's score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CRISPR Therapeutics Neutral
Tourmaline Bio Neutral

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CRISPR Therapeutics currently has a consensus price target of $64.53, suggesting a potential upside of 23.19%. Tourmaline Bio has a consensus price target of $47.94, suggesting a potential downside of 0.07%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than Tourmaline Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
2 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.53
Tourmaline Bio
1 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

CRISPR Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.

Tourmaline Bio is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR TherapeuticsN/AN/A-$581.60M-$6.52N/A
Tourmaline BioN/AN/A-$73.21M-$3.43N/A

Summary

CRISPR Therapeutics beats Tourmaline Bio on 9 of the 15 factors compared between the two stocks.

How does Tourmaline Bio compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Tourmaline Bio (NASDAQ:TRML) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Tourmaline Bio has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -7,973.33%. Tourmaline Bio's return on equity of -30.50% beat Dianthus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dianthus Therapeutics-7,973.33% -38.85% -36.42%
Tourmaline Bio N/A -30.50%-29.63%

In the previous week, Dianthus Therapeutics had 5 more articles in the media than Tourmaline Bio. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 0 mentions for Tourmaline Bio. Dianthus Therapeutics' average media sentiment score of 0.63 beat Tourmaline Bio's score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Dianthus Therapeutics Positive
Tourmaline Bio Neutral

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dianthus Therapeutics currently has a consensus price target of $115.55, suggesting a potential upside of 28.04%. Tourmaline Bio has a consensus price target of $47.94, suggesting a potential downside of 0.07%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than Tourmaline Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00
Tourmaline Bio
1 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Dianthus Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500.

Tourmaline Bio has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dianthus Therapeutics$2.04M2,413.30-$162.34M-$4.10N/A
Tourmaline BioN/AN/A-$73.21M-$3.43N/A

Summary

Tourmaline Bio beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tourmaline Bio compare to Legend Biotech?

Tourmaline Bio (NASDAQ:TRML) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

In the previous week, Legend Biotech had 8 more articles in the media than Tourmaline Bio. MarketBeat recorded 8 mentions for Legend Biotech and 0 mentions for Tourmaline Bio. Legend Biotech's average media sentiment score of 0.22 beat Tourmaline Bio's score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Tourmaline Bio Neutral
Legend Biotech Neutral

Tourmaline Bio has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tourmaline BioN/AN/A-$73.21M-$3.43N/A
Legend Biotech$1.03B5.13-$296.80M-$0.80N/A

Tourmaline Bio currently has a consensus price target of $47.94, suggesting a potential downside of 0.07%. Legend Biotech has a consensus price target of $58.31, suggesting a potential upside of 104.52%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Tourmaline Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tourmaline Bio
1 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Legend Biotech
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.67

91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 13.0% of Tourmaline Bio shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tourmaline Bio has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.

Tourmaline Bio has a net margin of 0.00% compared to Legend Biotech's net margin of -28.86%. Legend Biotech's return on equity of -21.93% beat Tourmaline Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Tourmaline BioN/A -30.50% -29.63%
Legend Biotech -28.86%-21.93%-13.21%

Summary

Legend Biotech beats Tourmaline Bio on 9 of the 15 factors compared between the two stocks.

How does Tourmaline Bio compare to Indivior?

Tourmaline Bio (NASDAQ:TRML) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

In the previous week, Indivior had 20 more articles in the media than Tourmaline Bio. MarketBeat recorded 20 mentions for Indivior and 0 mentions for Tourmaline Bio. Indivior's average media sentiment score of 0.81 beat Tourmaline Bio's score of 0.00 indicating that Indivior is being referred to more favorably in the news media.

Company Overall Sentiment
Tourmaline Bio Neutral
Indivior Positive

Indivior has higher revenue and earnings than Tourmaline Bio. Tourmaline Bio is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tourmaline BioN/AN/A-$73.21M-$3.43N/A
Indivior$1.24B3.90$210M$1.9520.30

Tourmaline Bio currently has a consensus price target of $47.94, suggesting a potential downside of 0.07%. Indivior has a consensus price target of $39.33, suggesting a potential downside of 0.65%. Given Tourmaline Bio's higher probable upside, equities research analysts clearly believe Tourmaline Bio is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tourmaline Bio
1 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Indivior
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00

91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 13.0% of Tourmaline Bio shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tourmaline Bio has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

Indivior has a net margin of 19.44% compared to Tourmaline Bio's net margin of 0.00%. Tourmaline Bio's return on equity of -30.50% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Tourmaline BioN/A -30.50% -29.63%
Indivior 19.44%-219.26%29.40%

Summary

Indivior beats Tourmaline Bio on 11 of the 16 factors compared between the two stocks.

How does Tourmaline Bio compare to Crinetics Pharmaceuticals?

Tourmaline Bio (NASDAQ:TRML) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 13.0% of Tourmaline Bio shares are owned by insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tourmaline Bio has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -6,046.22%. Tourmaline Bio's return on equity of -30.50% beat Crinetics Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tourmaline BioN/A -30.50% -29.63%
Crinetics Pharmaceuticals -6,046.22%-41.46%-37.43%

In the previous week, Crinetics Pharmaceuticals had 12 more articles in the media than Tourmaline Bio. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 0 mentions for Tourmaline Bio. Crinetics Pharmaceuticals' average media sentiment score of 0.96 beat Tourmaline Bio's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Tourmaline Bio Neutral
Crinetics Pharmaceuticals Positive

Tourmaline Bio has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Tourmaline Bio is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tourmaline BioN/AN/A-$73.21M-$3.43N/A
Crinetics Pharmaceuticals$7.70M558.30-$465.32M-$4.94N/A

Tourmaline Bio presently has a consensus price target of $47.94, suggesting a potential downside of 0.07%. Crinetics Pharmaceuticals has a consensus price target of $76.75, suggesting a potential upside of 88.34%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Tourmaline Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tourmaline Bio
1 Sell rating(s)
9 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Crinetics Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90

Tourmaline Bio has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Summary

Crinetics Pharmaceuticals beats Tourmaline Bio on 9 of the 16 factors compared between the two stocks.

Get Tourmaline Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRML vs. The Competition

Export
MetricTourmaline BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.23B$3.10B$6.25B$11.87B
Dividend YieldN/A1.91%2.73%5.21%
P/E Ratio-13.9918.3729.0428.47
Price / SalesN/A281.30476.6160.92
Price / CashN/A50.4327.6236.52
Price / Book4.104.339.676.67
Net Income-$73.21M$72.19M$3.55B$332.53M

Tourmaline Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRML
Tourmaline Bio
0.0738 of 5 stars		$47.98
flat		$47.94
-0.1%		N/A$1.23BN/AN/A44
CRSP
CRISPR Therapeutics
2.4594 of 5 stars		$52.06
+2.1%		$64.53
+24.0%		N/A$4.92B$3.51MN/A460
DNTH
Dianthus Therapeutics
3.1565 of 5 stars		$83.67
-4.0%		$115.55
+38.1%		N/A$4.75B$2.04MN/A80
LEGN
Legend Biotech
3.3318 of 5 stars		$23.56
-0.4%		$58.31
+147.5%		N/A$4.37B$1.03BN/A2,965
INDV
Indivior
2.8111 of 5 stars		$34.43
+0.3%		$39.33
+14.2%		N/A$4.18B$1.24B20.991,051

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TRML) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel